For patients with metastatic adenocarcinoma of the lung, do you base any treatment decisions on EGFR gene amplification?  

There are no proven predictive uses for EGFR amplification in lung cancer. In a negative trial of necitmumab, patients with EGFR amplification had a positive outcome in the EGFR amplified subset, but this was an unplanned analysis and is thus hypothesis generating rather than proven. The hypothesis ...

Not at this time. When decoding the molecular reports for our patients with NSCLC, the relevant EGFR changes are limited to mutations. Overexpression and amplification have not been useful predictive markers for our current EGFR directed therapies. In fact, amplification of wild type EGFR may even d...